Table 3.
Normal PWA (n=12,204) | aPWA (n=2698) | P-value | |
---|---|---|---|
Definite thrombotic stroke (n=481) | 405 | 76 | |
Person-years | 258,463 | 46,360 | |
Incidence rate (95% CI)* | 1.57 (1.42–1.73) | 1.64 (1.30–2.04) | |
HR (95% CI), Model 0† | 1 (REF) | 1.01 (0.79–1.30) | 0.92 |
HR (95% CI), Model 1‡ | 1 (REF) | 1.18 (0.92–1.52) | 0.19 |
HR (95% CI), Model 2§ | 1 (REF) | 1.30 (1.01–1.67) | 0.04 |
HR (95% CI), Model 3|| | 1 (REF) | 1.32 (1.03–1.71) | 0.03 |
Definite cardioembolic stroke (n=176) | 132 | 44 | |
Person-years | 258,463 | 46,360 | |
Incidence rate (95% CI)* | 0.51 (0.43–0.60) | 0.95 (0.70–1.26) | |
HR (95% CI), Model 0† | 1 (REF) | 1.69 (1.20–2.37) | 0.003 |
HR (95% CI), Model 1‡ | 1 (REF) | 2.31 (1.63–3.28) | <0.0001 |
HR (95% CI), Model 2§ | 1 (REF) | 2.55 (1.78–3.65) | <0.0001 |
HR (95% CI), Model 3|| | 1 (REF) | 2.04 (1.42–2.95) | 0.0001 |
per 1000 person-years
Unadjusted cox proportional hazard model
Model 0 + adjustment for age, sex, and race/study center variable updated until the development of aPWA, censoring, or definite ischemic stroke, whichever occurred first
Model 1 + adjustment for smoking status, body mass index, systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, coronary heart disease, left ventricular hypertrophy, heart failure, use of anticoagulants updated until the development of aPWA, censoring, or definite ischemic stroke, whichever occurred first
Model 2 + atrial fibrillation updated to end of follow-up
Abbreviations: Confidence interval (CI), hazard ratio (HR), P-wave axis (PWA), abnormal P-wave axis (aPWA), reference (REF)